Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase III VANISH-306 study of oral ibrexafungerp in VVC meets primary endpoint

April 21, 2020

Cara reports topline data from KALM-2 trial of Korsuva in hemodialysis patients with pruritus

April 21, 2020

IMDC recommends continuation of phase III trial of eryaspase in advanced pancreatic cancer

April 21, 2020

Nucorion begins first-in-human study of NCO-48 fumarate for hepatitis B

April 21, 2020

New nitric oxide production inhibitors presented by FronThera US Pharmaceuticals

April 21, 2020

Cardurion Pharmaceuticals synthesizes new CAMK2 inhibitors

April 21, 2020

Genzyme identifies new GALC inhibitors

April 21, 2020

Regenacy Pharmaceuticals discloses HDAC1 and/or HDAC2 inhibitors

April 21, 2020

Arbidol shows superior efficacy compared to lopinavir/ritonavir in treating COVID-19

April 21, 2020

RAPT Therapeutics patents USP7 inhibitors

April 21, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...